Abzu selected partner for EU project Elegant North to create a new strategy for handling data on rare diseases

Abzu® is a selected partner for project Elegant North, an EU project funded by Interreg Öresund-Kattegat-Skagerrak, which aims to create a new strategy for handling data on rare diseases.

Rare diseases, although individually rare, are collectively common. Insufficient disease understanding directly contributes to a lack of treatment efficacy or simply a lack of available treatments. This costs the Nordic healthcare system billions of kroner a year and leaves those diagnosed with a rare disease – half of which are children1 – helpless.

To address the deficiency of treatments for rare diseases, the selected partners in project Elegant North will create a cross-border, rare disease data-sharing platform to foster cross-sector collaboration between researchers, companies, and healthcare systems. The partners expect this effort to result in innovative technological solutions for improved personalized medicine options for patients diagnosed with a rare disease.

“What a great opportunity for Abzu’s scientists and data scientists to collaborate with an extensive network – from bench to bedside – to better understand what causes rare diseases,” says Marco Salvatore, Head of Target and Biomarker Discovery at Abzu.

Abzu will be responsible for the bioinformatics and precision medicine work package. Abzu’s experts in disease understanding and bioinformatics – combined with their proprietary QLattice® discovery engine – will develop the algorithms used to analyze clinical and genetic data for new diagnostic and therapeutic options for a personalized medicine approach to rare diseases.

In addition to Abzu, the partners participating in project Elegant North are Oslo University Hospital (Oslo Universitetssykehus), the Capital Region of Denmark (Region Hovedstaden), The Technical University of Denmark (Danmarks Tekniske Universitet), Plesner (Plesner Advokatpartnerselskab), and the Scania Regional Council (Region Skåne).

The total budget for project Elegant North is 4.717.261 euros. The formal project period will run from 1 September 2023 to 31 August 2026.


1 Haendel M, Vasilevsky N, Unni D, et al. How many rare diseases are there? Nat Rev Drug Discov. 2020;19(2):77–78.

About Abzu

Abzu empowers scientists to bring drugs to market faster by accelerating their exploration and understanding.

From disease understanding to drug discovery, Abzu has introduced new methods and technology to drive drug discoveries and reduce R&D costs for biotech and pharmaceutical companies.

Founded in January 2018, Abzu is a deep tech startup with offices in Copenhagen, Denmark and Barcelona, Spain.

To learn more, visit: www.abzu.ai

About project Elegant North

The project Elegant North (Exploring Leukemia, Education, Genetics And Technologies; New Option for Rare diseases Toward Health) aims to create a new strategy for handling data on rare diseases.

Project Elegant North focuses on innovation and entrepreneurship within selected partners in Sweden, Norway, and Denmark in order to strengthen cross-sector collaboration between the healthcare system and private companies with a view to innovative technological solutions for personalized medicine in the field of rare diseases.

About Interreg Öresund-Kattegat-Skagerrak

Interreg Öresund-Kattegat-Skagerrak is an EU program tasked with investing 140 million euros from 2021 to 2027 in projects that work to solve societal challenges across borders in southern Scandinavia.

Learn more at https://interreg-oks.eu/

Share this press release

More press releases

Get notified

Subscribe to receive a notification when there’s news about Abzu. You can opt out at any time.

We’re cookieless, and our privacy policy is actually easy to read.

Contact Abzu

It’s easy to get in touch with an Abzoid.

Contact form

Fill out the form below, and an Abzoid will be in touch in 24 hours.

Email us

Email Marketing at elyse.sims@abzu.ai or info@abzu.ai.

Call us

Reach us during standard CET business hours at +45 31 23 47 64.